According to the latest report by IMARC Group, titled "Global Gene Therapy Market Size, Share, Industry Trends, Growth, Opportunity and Forecast 2022-2027", The global gene therapy market reached a value of US$ 3.77 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 9.5 Billion by 2027 exhibiting a CAGR of 15.60% during 2022-2027.
Base Year: 2021
Forecast Year: 2022-2027
Gene Therapy Market Trends and Drivers:
The global gene therapy market is primarily driven by the growing incidences of inherited and acquired diseases, such as cancer, diabetes, cystic fibrosis, heart disease, and acquired immunodeficiency syndrome (AIDS).
Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/gene-therapy-market/requestsample
Additionally, the rising government support and funding for gene therapy research is another major growth-inducing factor. Furthermore, the leading players are developing advanced gene therapy products that offer a safer and non-addictive alternative to opioids in treating numerous chronic pain conditions like lower back pain, which is catalyzing the market growth.
Other factors, including the aging population, increasing approvals of new gene therapy technologies, easy access to healthcare facilities, and technological advancements, are also anticipated to drive the market further.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Global Gene Therapy Market 2022-2027 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc.,
Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bluebird Bio Inc., Mustang Bio
Inc. (Fortress Biotech Inc.), Novartis AG, Orchard Therapeutics plc, UniQure
N.V. and Voyager Therapeutics Inc.
The report has segmented the market on the basis of region, gene type, vector type, delivery method and application
Breakup by Gene Type:
· Tumor Suppressor
· Suicide Gene
· Growth Factors
Breakup by Vector Type:
· Viral Vector
o Adeno-Associated Virus
o Herpes Simplex Virus
o Vaccinia Virus
· Non-Viral Techniques
o Naked and Plasmid Vectors
o Gene Gun
Breakup by Delivery Method:
· In-Vivo Gene Therapy
· Ex-Vivo Gene Therapy
Breakup by Application:
· Oncological Disorders
· Rare Diseases
· Cardiovascular Diseases
· Neurological Disorders
· Infectious Disease
Breakup by Region:
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/gene-therapy-market
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800